08 Nov, EOD - Indian

SENSEX 79486.32 (-0.07)

Nifty 50 24148.2 (-0.21)

Nifty Bank 51561.2 (-0.68)

Nifty IT 42050.15 (0.71)

Nifty Midcap 100 56352 (-1.33)

Nifty Next 50 69774.2 (-1.23)

Nifty Pharma 22542.25 (0.07)

Nifty Smallcap 100 18445.6 (-1.70)

08 Nov, EOD - Global

NIKKEI 225 39500.37 (0.30)

HANG SENG 20728.19 (-1.07)

S&P 6037 (0.35)

Login/Signup
LOGIN HERE
Cancel

Jagsonpal Pharmaceuticals Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 507789 | NSE Symbol : JAGSNPHARM | ISIN : INE048B01027 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
16-Oct-2024 23-Oct-2024 Quarterly Results JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2024 inter alia to consider and approve (i) Unaudited Financial Results of the Company for the quarter and half year ended September 30 2024. (ii) Proposal for sub-division/split of existing Equity Shares of the Company having a face value of Rs. 5/- each fully paid up in such manner as may be determined by the Board of Directors subject to the approval of Equity Shareholders of the Company and other applicable approval(s) (if any). Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the following: 1. Unaudited Financial Results along with Limited Review Report issued by the Statutory Auditors of the Company for the quarter and half year ended September 30, 2024. 2. Sub-division/ split of the existing Equity Shares of the Company, such that each Equity Share having face value of Rs. 5/- (Rupees Five only) each fully paid-up, be sub-divided/split into such number of Equity Shares having face value of Rs. 2 each fully paid-up, subject to the approval of Equity Shareholders of the Company through Postal Ballot. Please find enclosed Unaudited financial result and limited review report for quarter and half year ended September 30, 2024 (As Per BSE Announcement Dated on: 23/10/2024)
31-Jul-2024 07-Aug-2024 Quarterly Results JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30 2024. Please find enclosed herewith Unaudited Financial Results along with limited review report for quarter ended June 30, 2024. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Financial Results for the quarter ended June 30, 2024. In this regard, kindly find enclosed the Unaudited Financial Results along with its Limited Review Report issued by the Statutory Auditors of the Company for the quarter ended June 30, 2024. The Board Meeting commenced at 05:40 p.m. and concluded at 06:25 p.m (As Per BSE Announcement Dated on: 07/08/2024)
13-May-2024 20-May-2024 Final Dividend JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2024 inter alia to consider and approve the Audited Financial Result of the company for the quarter and year ended March 31 2024 and recommendation of dividend if any for the financial year ended March 31 2024. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Audited (Standalone) Financial Results for the quarter and year ended March 31, 2024. In this regard, kindly find enclosed the following: 1.Audited (Standalone) Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2024. 2. The Board recommended a dividend of Rs. 5/- (100%) per equity share for the financial year ended March 31, 2024. (As Per BSE Announcement dated on 20.05.2024)
25-Jan-2024 02-Feb-2024 Quarterly Results JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2024 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2023. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2023. In this regard, kindly find enclosed the Unaudited Financial Results along with its Limited Review Report by the Statutory Auditors of the Company for the quarter and nine months ended December 31, 2023. The Board Meeting commenced at 04:15 p.m. and concluded at 05:05 p.m. Please find enclosed the intimation on change in Key Managerial Personnel. (As Per BSE Announcement dated on 02.02.2024)
26-Oct-2023 03-Nov-2023 Quarterly Results JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of Jagsonpal Pharmaceuticals Limited (the Company) is scheduled to be held on Friday November 03 2023 to consider and approve inter-alia the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2023 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Financial Results for the quarter and half year ended September 30, 2023. In this regard, kindly find enclosed the Unaudited Financial Results along with its Limited Review Report by the Statutory Auditors of the Company for the quarter and half year ended September 30, 2023. The Board Meeting commenced at 12:45 p.m. and concluded at 13:40 p.m. Please enclose herewith quarterly and half yearly financial results with limited review report for the quarter and half year ended on September 30, 2023. Board of Director at its meeting held today, inter alia considered and approved in principle divestment of Company''s Faridabad facility. (As per BSE Announcement Dated on 03/11/2023)
25-Jul-2023 02-Aug-2023 Quarterly Results JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of Jagsonpal Pharmaceuticals Limited (the Company) is scheduled to be held on Wednesday August 02 2023 to consider and approve inter-alia the Unaudited Financial Results of the Company for the quarter ended June 30 2023. Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Financial Results for the quarter ended June 30, 2023. In this regard, kindly find enclosed the Unaudited Financial Results along with its Limited Review Report by the Statutory Auditors of the Company for the quarter ended June 30, 2023. Kindly find enclosed the Unaudited Financial Results for the quarter ended June 30, 2023 along with Limited Review Report (As per BSE Announcement Dated on 02/08/2023)
15-May-2023 23-May-2023 Dividend JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2023 inter alia to consider and approve a) the Audited Financial Results of the Company for the quarter and year ended March 31 2023. b) recommendation of dividend if any for the financial year ended March 31 2023. The Board of Directors at their meeting held today have recommended dividend of Rs. 5/- per equity share of face value of Rs. 5/- for the financial year ended March 31, 2023. The dividend shall be payable after it is approved by the shareholders at the 44th Annual General Meeting of the Company. (As per BSE Announcement Dated on 23/05/2023)
31-Jan-2023 08-Feb-2023 Quarterly Results JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2023 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please be informed that a Meeting of Board of Directors of the Company will be held on Wednesday February 8 2023 inter alia to consider and approve the Standalone Unaudited Financial Results of the Company for the quarter ended December 31 2022. As per the provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for designated persons of the Company was closed on January 1 2023 and will remain closed until February 10 2023. This is for your information purposes. Unaudited financial results quarter and nine months ended 31st dec, 2022. (As Per BSE Announcement dated on 08.02.2023)
03-Nov-2022 09-Nov-2022 Quarterly Results JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2022 inter alia to consider and approve Standalone Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2022; OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON NOVEMBER 09TH, 2022. Financial Results for the quarter and half year ended 30 September, 2022. (As Per BSE Announcement Dated on 09/11/2022)
04-Aug-2022 09-Aug-2022 Quarterly Results JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2022 inter alia to consider and approve the Unaudited Financial Results for the quarter ended 30th June 2022. Accordingly trading window for designated persons of the Company was closed on July 1 2022 and will remain closed until August 11 2022. Please find attached the Unaudited Financial Results (Standalone) of the Company along with Limited Review Report of the Statutory Auditors for the quarter ended June 30, 2022, as approved by the Board of Directors of the Company at their meeting held today, along with a press release issued in this regard. (As Per BSE Announcement Dated on 09.08.2022)
16-Jul-2022 16-Jul-2022 Change in Directors Appointment of Mr. Manish Gupta as the Managing Director of the company. Authorization for determining materiality of an event or information under the SEBI LODR.
30-Jun-2022 29-Jun-2022 Change in Directors Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015
22-May-2022 30-May-2022 Accounts JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve The Standalone Audited Financial Results of the Company for the quarter and year ended 31st March 2022. This is to intimate that the Board of Directors of the Company at their meeting held today, (i.e. Monday, the 30th Day of May, 2022), commenced at 1200 hours and concluded on 1755 hours at registered office, have inter alia, approved and taken on record the following: 1. Pursuant to Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, Audited Standalone Financial Results of the Company for the Quarter and financial year ended 31st March, 2022; 2. Audit Report for the Quarter and financial year ended 31st March, 2022; 3. Approved the Directors' Report together with Management Discussion and Analysis Report along with Report on Corporate Governance; 4. Other Agenda items. Further, we declare that the Report of Auditors are with unmodified opinion with respect to the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2022. Kindly take the above on record & oblige. Audited Financial Results for the quarter and financial year ended 31 March, 2022. (As Per BSE Announcement Dated on 30/05/2022)
04-May-2022 13-May-2022 Amendments in Articles of Assoc. JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2022 inter alia to consider and approve the alteration in AOA and other routine matters. Outcome of the Board Meeting. (As Per BSE Announcement Dated on 13.05.2022)
03-Feb-2022 11-Feb-2022 Quarterly Results JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2022 inter alia to consider and approve 1. The Unaudited Financial Results for the quarter and nine months ended 31.December.2021; 2. The Limited Review Report on Un-Audited Financial Results of the Company for the quarter ended 31th December 2021; 3. The appointment of Chief Financial Officer of the Company; 4. Any other agenda item as place before the Board. This is to intimate that the Board of Directors of the Company at their meeting held today, (i.e. Friday, the 11th Day of February, 2022), have inter alia, approved and taken on record the following: 1. The Un-audited Financial Results for the quarter and nine months ended 31st December, 2021; 2. Limited Review Report on the Un-audited Financial Results for the said quarter; 3. Took note of Resignation of Mr. Sanjiv Kumar Dudeja from the position of Chief Financial Officer of the Company; 4. Appointment of Mr. S.V. Subha Rao as the Chief Financial Officer with effect from 11th February, 2022; 5. Other agenda items. Results for the quarter and nine months ended 31.12.2021. The Board Meeting was concluded at 1315 hours. (As Per BSE Announcement dated on 11.02.2022)
1 2